Ark postpones LSE (London Stock Exchange) float:
This article was originally published in Clinica
Unusual market conditions" have prompted UK biotechnology company Ark Therapeutics to postpone its flotation on the London Stock Exchange. The London-based company, which develops medical products and pharmaceuticals aimed at vascular disease and cancer, had planned to raise up to $57 million in the offering (see Clinica No 1003, p 14). CEO Nigel Parker stressed that the company had been "extremely well received" at all investor meetings and that it intended to return to the capital markets when conditions were more favourable.